For patients 12 years of age and older with mild to moderate atopic dermatitis who have not reacted well to alternative topical prescription treatments, rufolitinib is approved for use. Furthermore, polycythemia Vera and myelofibrosis are among the ailments for which Roxolitinib is approved when taken orally, demonstrating the drug’s adaptability in treating a range of hematologic and inflammatory illnesses.